Meta-analysis of articles evaluating routine intraocular pressure control in monotherapy in the United States and Germany

European Journal of Ophthalmology

Volumn 19, Issue 5, 2009, Pages 769-775

  Stewart, William C ^a,d   Pfeiffer, Norbert ^b   Mathis, Heather M ^c  

^a University of South Carolina   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Charleston Research Company LLC   (United States)

^d NONE   (United States)

Author keywords

Europe; Glaucoma treatment; Intraocular pressure; United States

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; LATANOPROST; PROSTAGLANDIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; EXFOLIATION SYNDROME; FEMALE; GERMANY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PIGMENTATION; PRIORITY JOURNAL; UNITED STATES;

AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; GERMANY; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; UNITED STATES;

EID: 70549101013     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900514     Document Type: Article

References (21)

1. Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 2nd ed. St. Louis: Mosby, Inc., 1996; 1575-1632.
2. Stewart WC. Clinical Practice of Glaucoma. Thorofare: SLACK, Inc., 1990; 297-333.
3. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141-7.
4. Thelen U, Christ T, Schnober D, Hofstetter HJ, Stewart WC. Midterm response with latanoprost therapy in German ocular hypertension patients. Curr Eye Res 2007; 32: 51-6.
5. Book SA. Essentials of statistics. In: Arthur AA, Rogers J, Bradley JW, eds. Testing Statistical Hypotheses. New York: McGraw-Hill; 1978: 204-6.
6. Stewart WC, Konstas AGP, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004; 20: 461-9.
7. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51-5.
8. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993; 116: 176-81.
9. Konstas AGP, Hollo G, Astakhov YS, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol 2004; 122: 29-33.
10. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
11. Kolker AE. Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc 1977; 75: 539-55.
12. Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology 1982; 89: 991-8.
13. Konstas AGP, Irkec MT, Teus MA, et al. Mean intraocular pressure and progression based on corneal thickness in patients with ocular hypertension. Eye 2009; 23: 73-8.
14. Camras CB, Alm A, Watsorv P, Stiemschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916-24.
15. Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol 1997; 123: 465-77.
16. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006; 124: 1230-8.
17. Stewart WC, Stewart JA, Nelson LA, Kruft B. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol 2008; 18: 199-204.
18. Zimmerman TJ, Stewart WG. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003; 19: 405-15.
19. Hamacher T, Schinzel M, Schölzel-Klatt A, et al. Short-term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/ timolol maleate 0.5% fixed combination from mono- and adjunctive therapies. Br J Ophthalmol 2004; 88: 1295-8.
20. Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol 2004; 14: 407-15.
21. Bayer A, Weiler W, Oeverhaus U, Skrotzki F-E, Stewart WC, Xplore Observation Group. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther 2004; 20: 470-8.